Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura
Takahiro
T
Department of Medicine, Kagawa Prefectural Central Hospital, Japan.
Tasaka
Taizo
T
Fujimoto
Miharu
M
Matsuhashi
Yoshiko
Y
Fukumot
Tetsuya
T
Mano
Shohei
S
Kuwajima
Minoru
M
Nagai
Masami
M
D058186:Acute Kidney Injury / Q000150:complications; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology*; D004211:Disseminated Intravascular Coagulation / Q000150:complications; D017809:Fatal Outcome; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D009336:Necrosis; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011014:Pneumonia / Q000150:complications; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D009363:Neoplasm Proteins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl